1. Report Introduction 2. Hypersomnia Market Overview at a Glance 2.1. Market Share Distribution of Hypersomnia in 2016 2.2. Market Share Distribution of Hypersomnia in 2028 3. Disease Background and Overview: Hypersomnia 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Hypersomnia in 7MM 4.3. Total Prevalent Patient Population of Hypersomnia in 7MM – By Countries 5. Epidemiology of Hypersomnia by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Hypersomnia 5.1.3. Sub-Type Specific cases of the Hypersomnia * 5.1.4. Sex- Specific Cases of the Hypersomnia * 5.1.5. Diagnosed Cases of the Hypersomnia 5.1.6. Treatable Cases of the Hypersomnia 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Hypersomnia 5.4.3. Sub-Type Specific cases of the Hypersomnia * 5.4.4. Sex- Specific Cases of the Hypersomnia * 5.4.5. Diagnosed Cases of the Hypersomnia 5.4.6. Treatable Cases of the Hypersomnia 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Hypersomnia 5.5.3. Sub-Type Specific cases of the Hypersomnia * 5.5.4. Sex- Specific Cases of the Hypersomnia * 5.5.5. Diagnosed Cases of the Hypersomnia 5.5.6. Treatable Cases of the Hypersomnia 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Hypersomnia 5.6.3. Sub-Type Specific cases of the Hypersomnia * 5.6.4. Sex- Specific Cases of the Hypersomnia * 5.6.5. Diagnosed Cases of the Hypersomnia 5.6.6. Treatable Cases of the Hypersomnia 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Hypersomnia 5.7.3. Sub-Type Specific cases of the Hypersomnia * 5.7.4. Sex- Specific Cases of the Hypersomnia * 5.7.5. Diagnosed Cases of the Hypersomnia 5.7.6. Treatable Cases of the Hypersomnia 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Hypersomnia 5.8.3. Sub-Type Specific cases of the Hypersomnia * 5.8.4. Sex- Specific Cases of the Hypersomnia * 5.8.5. Diagnosed Cases of the Hypersomnia 5.8.6. Treatable Cases of the Hypersomnia 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Hypersomnia 5.9.3. Sub-Type Specific cases of the Hypersomnia * 5.9.4. Sex- Specific Cases of the Hypersomnia * 5.9.5. Diagnosed Cases of the Hypersomnia 5.9.6. Treatable Cases of the Hypersomnia 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Hypersomnia 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Hypersomnia 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Hypersomnia : 7MM Market Analysis 12.1. 7MM Market Size of Hypersomnia 12.2. 7MM Percentage Share of drugs marketed for Hypersomnia 12.3. 7MM Market Sales of Hypersomnia by Products 13. Hypersomnia : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Hypersomnia in United States 13.1.2. Percentage Share of drugs marketed for Hypersomnia in United States 13.1.3. Market Sales of Hypersomnia by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Hypersomnia in Germany 13.2.1.2. Percentage Share of drugs marketed for Hypersomnia in Germany 13.2.1.3. Market Sales of Hypersomnia by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Hypersomnia in France 13.2.2.2. Percentage Share of drugs marketed for Hypersomnia in France 13.2.2.3. Market Sales of Hypersomnia by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Hypersomnia in Italy 13.2.3.2. Percentage Share of drugs marketed for Hypersomnia in Italy 13.2.3.3. Market Sales of Hypersomnia by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Hypersomnia in Spain 13.2.4.2. Percentage Share of drugs marketed for Hypersomnia in Spain 13.2.4.3. Market Sales of Hypersomnia by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Hypersomnia in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Hypersomnia in United Kingdom 13.2.5.3. Market Sales of Hypersomnia by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Hypersomnia in Japan 13.3.2. Percentage Share of drugs marketed for Hypersomnia in Japan 13.3.3. Market Sales of Hypersomnia by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Hypersomnia in 7MM Table 2: Total Prevalent/Incident Cases of the Hypersomnia in 7MM by Countries Table 3: Prevalent/Incident Cases of the Hypersomnia in United States (2016-2028) Table 4: Sub-Type Specific cases of the Hypersomnia in United States (2016-2028) Table 5: Sex- Specific Cases of the Hypersomnia in United States (2016-2028) Table 6: Diagnosed Cases of the Hypersomnia in United States (2016-2028) Table 7: Treatable Cases of the Hypersomnia in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Hypersomnia in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Hypersomnia in Germany (2016-2028) Table 10: Sex- Specific Cases of the Hypersomnia in Germany (2016-2028) Table 11: Diagnosed Cases of the Hypersomnia in Germany (2016-2028) Table 12: Treatable Cases of the Hypersomnia in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Hypersomnia in France (2016-2028) Table 14: Sub-Type Specific cases of the Hypersomnia in France (2016-2028) Table 15: Sex- Specific Cases of the Hypersomnia in France (2016-2028) Table 16: Diagnosed Cases of the Hypersomnia in France (2016-2028) Table 17: Treatable Cases of the Hypersomnia in France (2016-2028) Table 18: Prevalent/Incident Cases of the Hypersomnia in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Hypersomnia in Italy (2016-2028) Table 20: Sex- Specific Cases of the Hypersomnia in Italy (2016-2028) Table 21: Diagnosed Cases of the Hypersomnia in Italy (2016-2028) Table 22: Treatable Cases of the Hypersomnia in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Hypersomnia in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Hypersomnia in Spain (2016-2028) Table 25: Sex- Specific Cases of the Hypersomnia in Spain (2016-2028) Table 26: Diagnosed Cases of the Hypersomnia in Spain (2016-2028) Table 27: Treatable Cases of the Hypersomnia in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Hypersomnia in UK (2016-2028) Table 29: Sub-Type Specific cases of the Hypersomnia in UK (2016-2028) Table 30: Sex- Specific Cases of the Hypersomnia in UK (2016-2028) Table 31: Diagnosed Cases of the Hypersomnia in UK (2016-2028) Table 32: Treatable Cases of the Hypersomnia in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Hypersomnia in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Hypersomnia in Japan (2016-2028) Table 35: Sex- Specific Cases of the Hypersomnia in Japan (2016-2028) Table 36: Diagnosed Cases of the Hypersomnia in Japan (2016-2028) Table 37: Treatable Cases of the Hypersomnia in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Hypersomnia in USD MM (2016-2028) Table 42:7MM- Market Share Hypersomnia by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Hypersomnia in USD MM (2016-2028) Table 45: United States-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Hypersomnia in USD MM (2016-2028) Table 48: Germany-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Hypersomnia in USD MM (2016-2028) Table 51: France-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Hypersomnia in USD MM (2016-2028) Table 54: Italy-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Hypersomnia in USD MM (2016-2028) Table 57: Spain-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Hypersomnia in USD MM (2016-2028) Table 60:UK-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Hypersomnia in USD MM (2016-2028) Table 63: Japan-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Hypersomnia in 7MM Figure 2: Total Prevalent/Incident Cases of the Hypersomnia in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Hypersomnia in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Hypersomnia in United States (2016-2028) Figure 5: Sex- Specific Cases of the Hypersomnia in United States (2016-2028) Figure 6: Diagnosed Cases of the Hypersomnia in United States (2016-2028) Figure 7: Treatable Cases of the Hypersomnia in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Hypersomnia in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Hypersomnia in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Hypersomnia in Germany (2016-2028) Figure 11: Diagnosed Cases of the Hypersomnia in Germany (2016-2028) Figure 12: Treatable Cases of the Hypersomnia in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Hypersomnia in France (2016-2028) Figure 14: Sub-Type Specific cases of the Hypersomnia in France (2016-2028) Figure 15: Sex- Specific Cases of the Hypersomnia in France (2016-2028) Figure 16: Diagnosed Cases of the Hypersomnia in France (2016-2028) Figure 17: Treatable Cases of the Hypersomnia in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Hypersomnia in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Hypersomnia in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Hypersomnia in Italy (2016-2028) Figure 21: Diagnosed Cases of the Hypersomnia in Italy (2016-2028) Figure 22: Treatable Cases of the Hypersomnia in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Hypersomnia in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Hypersomnia in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Hypersomnia in Spain (2016-2028) Figure 26: Diagnosed Cases of the Hypersomnia in Spain (2016-2028) Figure 27: Treatable Cases of the Hypersomnia in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Hypersomnia in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Hypersomnia in UK (2016-2028) Figure 30: Sex- Specific Cases of the Hypersomnia in UK (2016-2028) Figure 31: Diagnosed Cases of the Hypersomnia in UK (2016-2028) Figure 32: Treatable Cases of the Hypersomnia in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Hypersomnia in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Hypersomnia in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Hypersomnia in Japan (2016-2028) Figure 36: Diagnosed Cases of the Hypersomnia in Japan (2016-2028) Figure 37: Treatable Cases of the Hypersomnia in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Hypersomnia in USD MM (2016-2028) Figure 42:7MM- Market Share Hypersomnia by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Hypersomnia in USD MM (2016-2028) Figure 45: United States-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Hypersomnia in USD MM (2016-2028) Figure 48: Germany-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Hypersomnia in USD MM (2016-2028) Figure 51: France-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Hypersomnia in USD MM (2016-2028) Figure 54: Italy-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Hypersomnia in USD MM (2016-2028) Figure 57: Spain-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Hypersomnia in USD MM (2016-2028) Figure 60:UK-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Hypersomnia in USD MM (2016-2028) Figure 63: Japan-Market Share Hypersomnia by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Hypersomnia by Therapies in USD MM (2016-2028)